Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study
Jeanne Tie, Joshua David Cohen, Yuxuan Wang et al. · Gut · 2018
OBJECTIVE: For patients with locally advanced rectal cancer (LARC), adjuvant chemotherapy selection following surgery remains a major clinical dilemma. Here, we investigated the ability of circulating tumour DNA (ctDNA) to improve risk stratification in patients with LARC. DESIGN: We enrolled patients with LARC (T3/T4 and/or N+) planned for neoadjuvant chemoradiotherapy. Plasma samples were collected pretreatment, postchemoradiotherapy and 4-10 weeks after surgery. Somatic mutations in individual patient's tumour were identified via massively parallel sequencing of 15 genes commonly mutated in colorectal cancer. We then designed personalised assays to quantify ctDNA in plasma samples. Patients received adjuvant therapy at clinician discretion, blinded to the ctDNA results. RESULTS: We analysed 462 serial plasma samples from 159 patients. ctDNA was detectable in 77%, 8.3% and 12% of pretreatment, postchemoradiotherapy and postsurgery plasma samples. Significantly worse recurrence-free survival was seen if ctDNA was detectable after chemoradiotherapy (HR 6.6; P<0.001) or after surgery (HR 13.0; P<0.001). The estimated 3-year recurrence-free survival was 33% for the postoperative ctDNA-positive patients and 87% for the postoperative ctDNA-negative patients. Postoperative ctDNA detection was predictive of recurrence irrespective of adjuvant chemotherapy use (chemotherapy: HR 10.0; P<0.001; without chemotherapy: HR 22.0; P<0.001). Postoperative ctDNA status remained an independent predictor of recurrence-free survival after adjusting for known clinicopathological risk factors (HR 6.0; P<0.001). CONCLUSION: Postoperative ctDNA analysis stratifies patients with LARC into subsets that are either at very high or at low risk of recurrence, independent of conventional clinicopathological risk factors. ctDNA analysis could potentially be used to guide patient selection for adjuvant chemotherapy.
Cited by 381 works. doi:10.1136/gutjnl-2017-315852
Authors
- Jeanne Tie
- Joshua David Cohen
- Yuxuan Wang
- Lu Li
- Michael Christie
- Koen Simons
- Hany Elsaleh
- Suzanne Kosmider
- Rachel Wong
- Desmond Yip
- Ben Tran
- David S. Rangiah
- Matthew Burge
- David Goldstein
- Madhu Sudan Singh
- Iain Skinner
- Ian G. Faragher
- Matthew A. Croxford
- Carolyn L. Bampton
References
- The National Comprehensive Cancer Network
- Preoperative versus Postoperative Chemoradiotherapy for Rectal Cancer
- Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
- Circulating mutant DNA to assess tumor dynamics
- Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data
- An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage
- Detection and quantification of rare mutations with massively parallel sequencing
- Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer